Abstract
Many trypanosomatid protozoa, such as those belonging to the Trypanosoma and Leishmania genera cause serious diseases to man. Such parasites present an unusual feature, a mitochondrial DNA arranged in catenated circles, known as kinetoplast DNA (kDNA). The replication of kDNA network is a complex process, which involves many proteins. Some of them are classified as topoisomerases and play essential biological roles, not only on kDNA synthesis, but also in the dynamics of the network topology, constituting the main target for drugs in kinetoplast. DNA binding drugs are also reported as chemotherapeutic agents against trypanosomatid infections. This review summarizes what is known about kinetoplast as a potential chemotherapeutic target for trypanosomatid protozoa.
Keywords: Chemotherapy, DNA binding drugs, kinetoplast, topoisomerases, trypanosomatids
Current Pharmaceutical Design
Title: Kinetoplast as a Potential Chemotherapeutic Target of Trypanosomatids
Volume: 14 Issue: 9
Author(s): Maria Cristina Machado Motta
Affiliation:
Keywords: Chemotherapy, DNA binding drugs, kinetoplast, topoisomerases, trypanosomatids
Abstract: Many trypanosomatid protozoa, such as those belonging to the Trypanosoma and Leishmania genera cause serious diseases to man. Such parasites present an unusual feature, a mitochondrial DNA arranged in catenated circles, known as kinetoplast DNA (kDNA). The replication of kDNA network is a complex process, which involves many proteins. Some of them are classified as topoisomerases and play essential biological roles, not only on kDNA synthesis, but also in the dynamics of the network topology, constituting the main target for drugs in kinetoplast. DNA binding drugs are also reported as chemotherapeutic agents against trypanosomatid infections. This review summarizes what is known about kinetoplast as a potential chemotherapeutic target for trypanosomatid protozoa.
Export Options
About this article
Cite this article as:
Machado Motta Cristina Maria, Kinetoplast as a Potential Chemotherapeutic Target of Trypanosomatids, Current Pharmaceutical Design 2008; 14 (9) . https://dx.doi.org/10.2174/138161208784041051
DOI https://dx.doi.org/10.2174/138161208784041051 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Luminescent Silica Nanoparticles for Cancer Diagnosis
Current Medicinal Chemistry Anticancer Activity of New Compounds Using Benzimidazole as a Scaffold
Anti-Cancer Agents in Medicinal Chemistry Occurrence and Biological Properties of Sphingolipids - A Review
Current Nutrition & Food Science Editorial (Hot Topic: Survival Signaling Through Focal Adhesion Kinase in Tumors)
Anti-Cancer Agents in Medicinal Chemistry Polymer Nanoparticles - A Novel Strategy for Administration of Paclitaxel in Cancer Chemotherapy
Current Medicinal Chemistry The Prognostic Impact of Pleural Invasion in Lung Cancer According to the UICC Classification
Current Respiratory Medicine Reviews The Epidermal Growth Factor Receptor as a Therapeutic Target in Glioblastoma Multiforme and other Malignant Neoplasms
Anti-Cancer Agents in Medicinal Chemistry Abrogation of the G2 Checkpoint by Inhibition of Wee-1 Kinase Results in Sensitization of p53-Deficient Tumor Cells to DNA-Damaging Agents
Current Clinical Pharmacology Streamlined In Vivo Selection and Screening of Human Prostate Carcinoma Avid Phage Particles for Development of Peptide Based In Vivo Tumor Imaging Agents
Combinatorial Chemistry & High Throughput Screening Bladder Cancer Stem Cells
Current Stem Cell Research & Therapy Biological Evaluation of Azomethine-dihydroquinazolinone Conjugates as Cancer and Cholinesterase Inhibitors
Medicinal Chemistry Development of RNA Aptamer-Based Therapeutic Agents
Current Medicinal Chemistry Fighting Fire with Fire: A Patent for the Combined Application of Oncolytic Herpes Viruses and Antiangiogenic Agents in the Battle Against Human Cancers
Recent Patents on Anti-Cancer Drug Discovery Standardization of Procedures for the Preparation of <sup>177</sup>Lu- and <sup>90</sup>Y-labeled DOTA-Rituximab Based on the Freeze-dried Kit Formulation
Current Radiopharmaceuticals Current Treatment Concepts of CML
Current Cancer Drug Targets Molecular Imaging of Therapeutic Potential of Reporter Probes
Current Drug Targets Inpatient Care of the HIV Infected Patient in the Highly Active Antiretroviral Therapy (HAART) Era
Current HIV Research Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer
Current Pharmaceutical Design Locked Nucleic Acid Holds Promise in the Treatment of Cancer
Current Pharmaceutical Design Novel Immunotherapeutic Strategies for Invasive Fungal Disease
Current Drug Targets - Cardiovascular & Hematological Disorders